Summary
Medtronic plc reported solid financial results for the second quarter of fiscal year 2024, with net sales increasing by 5% to $7.98 billion and diluted earnings per share (EPS) of $0.68 compared to $0.32 in the prior year quarter. For the six-month period, net sales grew 5% to $15.69 billion, and diluted EPS was $1.28, up from $1.02 in the prior year. The company demonstrated continued revenue growth across its key segments, including Cardiovascular, Neuroscience, Medical Surgical, and Diabetes, driven by strong performance in specific product lines like Micra, TAVR, Core Spine, and the MiniMed 780G insulin pump system. Despite facing inflationary pressures and supply chain challenges, Medtronic maintained its commitment to innovation and strategic growth initiatives, including pending acquisitions and new product launches, positioning the company for sustained performance.
Financial Highlights
55 data points| Revenue | $7.98B |
| Cost of Revenue | $2.76B |
| Gross Profit | $5.22B |
| SG&A Expenses | $2.69B |
| Operating Income | $1.34B |
| Interest Expense | $180.00M |
| Net Income | $909.00M |
| EPS (Basic) | $0.68 |
| EPS (Diluted) | $0.68 |
| Shares Outstanding (Basic) | 1.33B |
| Shares Outstanding (Diluted) | 1.33B |
Key Highlights
- 1Net sales increased by 5% to $7.98 billion for the second quarter of fiscal year 2024, and by 5% to $15.69 billion for the first six months.
- 2Diluted Earnings Per Share (EPS) was $0.68 for the quarter, a significant increase from $0.32 in the prior year, and $1.28 for the six-month period, up from $1.02.
- 3All four major business segments (Cardiovascular, Neuroscience, Medical Surgical, and Diabetes) showed year-over-year revenue growth.
- 4The Cardiovascular segment saw a 6% increase in net sales, driven by products like Micra and TAVR.
- 5The Neuroscience segment's net sales grew 5%, with strong contributions from Core Spine and Neurosurgery.
- 6The Diabetes segment reported a 10% increase in net sales for the quarter, driven by the MiniMed 780G insulin pump system's global expansion.
- 7Medtronic repurchased approximately 2.3 million shares for $186 million during the fiscal second quarter under its $6.0 billion share repurchase program, with approximately $2.0 billion remaining.